Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis

被引：0

作者：

Luttwak, Efrat ^{[1
]}

Robin, Edith Tama ^{[2
]}

Drill, Esther ^{[3
]}

Boardman, Alexander ^{[1
]}

Caron, Philip ^{[1
]}

Epstein-Peterson, Zachary ^{[1
]}

Falchi, Lorenzo ^{[1
]}

Ghione, Paola ^{[1
]}

Hamlin, Paul A. ^{[1
]}

Horwitz, Steven M. ^{[1
]}

Intlekofer, Andrew M. ^{[1
]}

Johnson, William ^{[1
]}

Kumar, Anita ^{[1
]}

Lue, Jennifer ^{[1
]}

Noy, Ariela ^{[1
]}

Owens, Colette ^{[1
]}

Palomba, Maria Lia ^{[1
]}

Steiner, Raphael ^{[1
]}

Stuver, Robert ^{[1
]}

Torka, Pallawi ^{[1
]}

Vardhana, Santosha ^{[1
]}

Zelenetz, Andrew D. ^{[1
]}

Salles, Gilles ^{[1
]}

Moskowitz, Craig H. ^{[4
]}

Moskowitz, Alison J. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY USA

[2] Ichan Sch Med Mt Sinai Morningside & Mt Sinai West, New York, NY USA

[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA

[4] Univ Miami Hlth Syst, Miami, FL USA

来源：

LEUKEMIA & LYMPHOMA | 2025年

关键词：

T-cell/histiocyte-rich B-cell lymphoma; diffuse large B-cell lymphoma; Rituximab; R-CHOP; Rchop/R-ICE; R-CHOP; CHEMOTHERAPY; MANAGEMENT; PET;

D O I：

10.1080/10428194.2025.2465553

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

T-cell/histiocyte-rich B-cell lymphoma (THRLBCL) is an uncommon variant of diffuse large B-cell lymphoma (DLBCL). Historically, it is considered an aggressive variant with poorer outcomes; however, recent analyses suggest that outcomes may be better for patients treated in the rituximab era. We reviewed THRLBCL cases who were diagnosed in MSKCC from January 2000 to October 2019. A total of 67 patients were included with a median follow-up of 5.4 years (0.5-13.8). Frontline treatment included R-CHOP or R-CHOP-based treatment in 48%, R-EPOCH in 12%, R-CHOP/R-ICE in 33% and other palliative treatments in 7.5%. In the whole cohort, 5-year EFS and OS was 59% and 79%, respectively. In an analysis of patients who received therapy with R-CHOP-14 x 4 followed by ICE/R-ICE x 3 compared to patients who were treated with R-CHOP or R-CHOP based treatment, CR rates were 95% and 70%, respectively (p = 0.023). The R-CHOP/R-ICE regimen was also associated with higher event-free survival (5-year EFS of 80% vs 50%; p = 0.006) and overall survival (5-year OS of 100% vs 72%; p = 0013). Our study demonstrates better outcomes among patients with THRLBCL compared to historical data. Our findings suggest that treatment with a higher intensity regimen with noncross resistance, such as R-CHOP/R-ICE is reasonable approach for patients with newly diagnosed THRLBCL.

引用

页数：8

共 28 条

[1] Hartmann S., Eichenauer D.A., Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma, Pathology, 52, 1, pp. 142-153, (2020)
[2] Achten R., Verhoef G., Vanuytsel L., Et al., T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity, J Clin Oncol, 20, 5, pp. 1269-1277, (2002)
[3] Ramsay A.D., Smith W.J., Isaacson P.G., T-cell-rich B-cell lymphoma, Am J Surg Pathol, 12, 6, pp. 433-443, (1988)
[4] Swerdlow S.H., Campo E., Pileri S.A., Et al., The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, 127, 20, pp. 2375-2390, (2016)
[5] Sukswai N., Lyapichev K., Khoury J.D., Et al., Diffuse large B-cell lymphoma variants: an update, Pathology, 52, 1, pp. 53-67, (2020)
[6] Tousseyn T., De Wolf-Peeters C., T cell/histiocyte-rich large B-cell lymphoma: an update on its biology and classification, Virchows Arch, 459, 6, pp. 557-563, (2011)
[7] El Weshi A., Akhtar S., Mourad W.A., Et al., T-cell/histiocyte-rich B-cell lymphoma: clinical presentation, management and prognostic factors: report on 61 patients and review of literature, Leuk Lymphoma, 48, 9, pp. 1764-1773, (2007)
[8] Bouabdallah R., Mounier N., Guettier C., Et al., T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis, J Clin Oncol, 21, 7, pp. 1271-1277, (2003)
[9] Lim M.S., Beaty M., Sorbara L., Et al., T-cell/histiocyte-rich large B-cell lymphoma: a heterogeneous entity with derivation from germinal center B cells, Am J Surg Pathol, 26, 11, pp. 1458-1466, (2002)
[10] Aki H., Tuzuner N., Ongoren S., Et al., T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma, Leuk Res, 28, 3, pp. 229-236, (2004)

← 1 2 3 →